3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
9
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Neurofibromatosis 1
1
Lymphatic Metastasis
1
Low-grade Serous Ovarian Cancer
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease Progression
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Brain Diseases
1
Blast Crisis
1
Astrocytoma
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Interventions
Cyclophosphamide
12
aldesleukin
9
fludarabine
8
fludarabine phosphate
7
pembrolizumab
6
Ipilimumab
5
Interleukin-2
5
Nivolumab
4
dabrafenib
2
Vemurafenib
2
Biopsy
2
Aminolevulinic Acid
2
varlilumab
1
trametinib
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
glembatumumab vedotin
1
eprenetapopt
1
epacadostat
1
encorafenib
1
cemiplimab
1
cabozantinib
1
binimetinib
1
bempegaldesleukin
1
abobotulinumtoxinA
1
X-Rays
1
Tranexamic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Skin Neoplasms
×
binimetinib
×
Clear all
NCT05926960
2026-03-09
PORTSIDE
Pfizer
Phase 2
Terminated
38 enrolled